DK2187880T3 - Sammensætninger og fremgangsmåder til behandling af makuladegeneration - Google Patents

Sammensætninger og fremgangsmåder til behandling af makuladegeneration

Info

Publication number
DK2187880T3
DK2187880T3 DK08830106.4T DK08830106T DK2187880T3 DK 2187880 T3 DK2187880 T3 DK 2187880T3 DK 08830106 T DK08830106 T DK 08830106T DK 2187880 T3 DK2187880 T3 DK 2187880T3
Authority
DK
Denmark
Prior art keywords
compositions
methods
macular degeneration
treating macular
treating
Prior art date
Application number
DK08830106.4T
Other languages
English (en)
Inventor
Ilyas Washington
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40452355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2187880(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Columbia filed Critical Univ Columbia
Application granted granted Critical
Publication of DK2187880T3 publication Critical patent/DK2187880T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DK08830106.4T 2007-09-12 2008-09-12 Sammensætninger og fremgangsmåder til behandling af makuladegeneration DK2187880T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99337907P 2007-09-12 2007-09-12
PCT/US2008/010676 WO2009035673A1 (en) 2007-09-12 2008-09-12 Compositions and methods for treating macular degeneration

Publications (1)

Publication Number Publication Date
DK2187880T3 true DK2187880T3 (da) 2014-03-10

Family

ID=40452355

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08830106.4T DK2187880T3 (da) 2007-09-12 2008-09-12 Sammensætninger og fremgangsmåder til behandling af makuladegeneration

Country Status (8)

Country Link
US (4) US8877809B2 (da)
EP (2) EP2187880B1 (da)
JP (2) JP5149388B2 (da)
DK (1) DK2187880T3 (da)
ES (1) ES2449150T3 (da)
PL (1) PL2187880T3 (da)
PT (1) PT2187880E (da)
WO (1) WO2009035673A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242704A1 (en) 2003-03-14 2004-12-02 University Of Washington, Techtransfer - Invention Licensing Stabilized mutant opsin proteins
BRPI0511396B1 (pt) 2004-06-18 2021-07-27 University Of Washington Uso de 9-cis-retinil éster e uso de um derivado de retinal sintético
EP2187880B1 (en) 2007-09-12 2013-12-18 The Trustees of Columbia University in the City of New York Compositions and methods for treating macular degeneration
JP6022746B2 (ja) 2008-02-11 2016-11-09 ユニヴァーシティ オブ ワシントン 加齢関連性網膜機能不全の治療及び予防方法
US20090312438A1 (en) * 2008-06-13 2009-12-17 Bernstein Paul S Compositions and Methods for Attenuating the Formation of A2E in the Retinal Pigment Epithelium
RU2546005C2 (ru) 2009-09-15 2015-04-10 Кью Эл Ти ИНК. Фармацевтические составы, содержащие 9-цис-ретиниловые сложные эфиры в липидном наполнителе
US9173856B2 (en) 2010-04-19 2015-11-03 Qlt Inc. Therapeutic regimen and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
CA2865935C (en) 2012-03-01 2021-12-14 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
US9730941B2 (en) 2012-06-07 2017-08-15 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of Pin1
ES2896173T3 (es) 2014-02-13 2022-02-24 Katairo Gmbh Procedimientos para la determinación de compuestos o composiciones para el tratamiento de enfermedades relacionadas con la lipofuscina y compuestos o composiciones
WO2015143190A1 (en) * 2014-03-21 2015-09-24 Beth Israel Deaconess Medical Center, Inc. Enhanced atra-related compounds derived from structure-activity relationships and modeling for inhibiting pin1
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
KR102276424B1 (ko) * 2014-10-06 2021-07-12 삼성전자주식회사 로-키나제 저해제를 포함하는 세포의 노화를 감소시키기 위한 조성물 및 그의 용도
US9173915B1 (en) 2014-10-10 2015-11-03 Peter F. Kador Antioxidant eye drops
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
WO2018112154A1 (en) * 2016-12-15 2018-06-21 Codiak Biosciences, Inc. Methods of measuring exosomes using intrinsic fluorescence
CN118121573B (zh) * 2022-12-01 2025-08-05 复旦大学 一种氘代维生素a及其衍生物的用途
WO2024263751A2 (en) * 2023-06-20 2024-12-26 The Trustees Of Columbia University In The City Of New York Novel co-drug, co-administration, and sequential administration of selective ttr ligand and c20-d3-retinol for elimination of mechanism-based ocular adverse effects in treating macular degeneration and ttr amyloidosis
WO2024263782A2 (en) * 2023-06-20 2024-12-26 The Trustees Of Columbia University In The City Of New York Novel co-drug, co-administration, and sequential administration of bispecific rbp4/ttr ligand and c20-d3-retinol for elimination of mechanism-based ocular adverse effects in treating macular degeneration and ttr amyloidosis
WO2025147467A1 (en) 2024-01-02 2025-07-10 Alkeus Pharmaceuticals, Inc. 10mg to 35mg of gildeuretinol for use in the treatment of stargardt disease
WO2025147228A1 (en) 2024-01-02 2025-07-10 Alkeus Pharmaceuticals, Inc. Treatment for asymptomatic stargardt disease patients with gildeuretinol acetate
WO2025153898A1 (en) * 2024-01-19 2025-07-24 Gene Company Pty Ltd Retinoid compositions and methods of use
WO2026050657A1 (en) 2024-08-30 2026-03-05 Alkeus Pharmaceuticals, Inc. Gildeuretinol for use for treating geographic atrophy and neovascular age-related macular degeneration
CN120441428A (zh) * 2025-05-15 2025-08-08 复旦大学 一种双异戊二烯衍生物及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310764A (en) * 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
US5508456A (en) 1993-07-30 1996-04-16 Ligand Pharmaceuticals Incorporated 9-cis tritium-labeled retinoids and intermediates, methods for their synthesis and methods for their use in discovering retinoid X receptor ligands
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US8198334B2 (en) * 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
US6593104B1 (en) * 1999-02-12 2003-07-15 University Of Iowa Research Foundation Macular degeneration diagnostics and therapeutics
US20030149997A1 (en) * 1999-02-19 2003-08-07 Hageman Gregory S. Diagnostics and therapeutics for arterial wall disruptive disorders
WO2001012776A2 (en) * 1999-08-16 2001-02-22 Human Genome Sciences, Inc. 18 human secreted proteins
US20040009907A1 (en) * 2001-02-26 2004-01-15 Alsobrook John P. Proteins and nucleic acids encoding same
US20030032078A1 (en) 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
NZ516873A (en) 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
US20040248919A1 (en) 2001-03-14 2004-12-09 Bell Michael Gregory Fluorinated trienes and their use as rxr modulators
US6660297B2 (en) 2001-03-23 2003-12-09 Bausch & Lomb Incorporated Nutritional supplement to treat macular degeneration
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
CA2507036A1 (en) * 2002-12-02 2004-06-17 Genvec, Inc. Materials and methods for treating ocular-related disorders
CA2525987A1 (en) 2003-06-05 2005-01-06 Charles Achkar Methods of treating hyperproliferative cell disorders
WO2005065669A1 (en) * 2003-12-19 2005-07-21 Alcon, Inc. Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
FR2864871A1 (fr) 2004-01-06 2005-07-08 Thomson Licensing Sa Methode de decouverte d'un reseau domestique et appareil implementant la methode
US7309487B2 (en) * 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
US7566808B2 (en) * 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
KR20070011379A (ko) 2004-03-17 2007-01-24 라스 미카엘 라르센 시각 사이클 억제에 의한 망막증의 예방
US20060089411A1 (en) 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
WO2006033734A2 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
WO2006047475A2 (en) * 2004-10-25 2006-05-04 Sytera, Inc. Detection and analysis of ophthalmically-relevant fluorescent molecules
JP2008519054A (ja) * 2004-11-04 2008-06-05 シリオン セラピューティクス， インコーポレイテッド レチノール−レチノール結合タンパク質（ｒｂｐ）−トランスチレチン（ｔｔｒ）複合体の形成のモジュレーター
CA2638753A1 (en) * 2004-12-08 2006-06-15 Sirion Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
PT1888548E (pt) * 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
WO2007037188A1 (ja) * 2005-09-27 2007-04-05 Sapporo Medical University 血管透過性亢進に起因する眼疾患の予防及び治療のための医薬
EP2187880B1 (en) 2007-09-12 2013-12-18 The Trustees of Columbia University in the City of New York Compositions and methods for treating macular degeneration
US8263601B2 (en) * 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
EP3090999A1 (en) * 2009-06-18 2016-11-09 Concert Pharmaceuticals Inc. Deuterated isoindoline-1, 3-dione derivatives as pde4 and tnf-alpha inhibitors
WO2012057723A1 (en) 2009-10-22 2012-05-03 Proksch, Roger Thermal measurements using multiple frequency atomic force microscopy

Also Published As

Publication number Publication date
EP2687208A1 (en) 2014-01-22
EP2187880A4 (en) 2010-09-08
JP5695017B2 (ja) 2015-04-01
EP2187880B1 (en) 2013-12-18
US20150133549A1 (en) 2015-05-14
PL2187880T3 (pl) 2014-05-30
ES2449150T3 (es) 2014-03-18
US8877809B2 (en) 2014-11-04
US9486432B2 (en) 2016-11-08
EP2187880A1 (en) 2010-05-26
US20170128403A1 (en) 2017-05-11
US20110034554A1 (en) 2011-02-10
WO2009035673A8 (en) 2009-07-02
WO2009035673A1 (en) 2009-03-19
PT2187880E (pt) 2014-03-25
USRE47045E1 (en) 2018-09-18
JP2010539168A (ja) 2010-12-16
JP5149388B2 (ja) 2013-02-20
JP2013049711A (ja) 2013-03-14

Similar Documents

Publication Publication Date Title
DK2187880T3 (da) Sammensætninger og fremgangsmåder til behandling af makuladegeneration
DK2894165T3 (da) Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
DK2323638T3 (da) Sammensætninger og fremgangsmåder til behandling af osteoartritis
DK2012789T3 (da) Fremgangsmåde til behandling af aldersrelateret makulær degeneration (AMD)
DK2203478T3 (da) Sammensætninger og fremgangsmåder til anvendelse af antistoffer mod sclerostin
DK2001611T3 (da) Fremgangsmåde og sammensætning til oprensning af jord
DK2796469T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
DK2326357T3 (da) Sammensætning og fremgangsmåde til behandling af vævsdefekter
DK3434687T3 (da) Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende samme
DK2212070T3 (da) Fremgangsmåde til behandling af træ
PT2144998T (pt) Métodos e composições para vírus vivos atenuados
DK2010501T3 (da) Imidazolbaserede forbindelser, sammensætninger omfattende disse og fremgangsmåder for deres anvendelse
DK2700651T3 (da) Monovalente sammensætninger til cd28-binding og fremgangsmåder til anvendelse heraf
DK2252342T3 (da) Indretninger og fremgangsmåder til behandling af skadet væv
DK2087002T3 (da) Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat
DK3181134T3 (da) Bifidobakterier til behandling af diabetes og relaterede tilstande
DK2081669T3 (da) Fremgangsmåde og anordning til fremstilling af granulater
DK3178490T3 (da) RSV F-proteinsammensætninger og fremgangsmåder til fremstilling af disse
EP2120561A4 (en) COMPOSITIONS FOR TREATING BIOFILMS, AND METHODS FOR THEIR USE
DK2066339T3 (da) Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner
BRPI0809573A8 (pt) composição, e, método
DK2766483T3 (da) Fremgangsmåder og sammensætninger til screening for og behandling af udviklingsforstyrrelser
DK3263112T3 (da) Sammensætninger og fremgangsmåder til undertrykkelse af endometriproliferationer
DK2361090T3 (da) Sammensætninger til behandling af centralt medieret kvalme og opkastning
DK2099489T3 (da) Sammensætninger og fremgangsmåder til behandling af en neoplasme